Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Xenetic Biosciences Inc
(NQ:
XBIO
)
4.115
UNCHANGED
Streaming Delayed Price
Updated: 2:35 PM EDT, Aug 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Xenetic Biosciences Inc
< Previous
1
2
Next >
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference
May 18, 2022
Live Webcast Presentation on Wednesday, May 25th at 4:00 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 18, 2022 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical...
From
Xenetic Biosciences, Inc.
Via
AccessWire
Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update
May 12, 2022
- Company completed recent transaction to expand oncology pipeline with in-licensing of DNase based platform comprising multiple therapeutic modalities - DNase based oncology platform has the potential...
From
Xenetic Biosciences, Inc.
Via
AccessWire
Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities
April 27, 2022
Transaction with CLS Therapeutics for DNase platform includes two pre-clinical development programs and creates near-term clinical development opportunity DNase based oncology platform has the...
From
Xenetic Biosciences, Inc.
Via
AccessWire
Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update
March 23, 2022
- XCARTTM continuing to advance toward IND-enabling studies - PolyXen® platform technology growing royalty stream through license agreement - Closed the year with $18.2 million of cash FRAMINGHAM, MA /...
From
Xenetic Biosciences, Inc.
Via
AccessWire
JTC Team to Host Virtual Investor 2022 Top Picks Conference on January 25th, 26th, and 27th
January 12, 2022
- Access the event and schedule of presenting companies at virtualinvestorco.com - - Live video webcast presentations of participating companies followed by interactive Q&A session - PITTSTOWN, NJ /...
From
JTC Team, LLC
Via
AccessWire
Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update
November 12, 2021
- Company advancing XCARTTM pre-clinical development plan toward IND-enabling studies - Strengthened cash position to fund operations through XCART IND filing with recently completed $12.5 million...
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent
September 09, 2021
Allowance bolsters intellectual property portfolio for differentiated personalized CAR T platform technology, XCART FRAMINGHAM, MA / ACCESSWIRE / September 9, 2021 / Xenetic Biosciences, Inc....
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
September 08, 2021
FRAMINGHAM, MA / ACCESSWIRE / September 8, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T...
From
Xenetic Biosciences, Inc.
Via
AccessWire
Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update
August 13, 2021
- Continued execution on XCART TM pre-clinical development plan and progress toward IND-enabling studies - Strong royalty growth with PolyXen® platform technology - Bolstered cash position with...
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market
July 28, 2021
FRAMINGHAM, MA / ACCESSWIRE / July 28, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T...
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Xenetic Biosciences, Inc. Announces $12.5 Million Private Placement Priced at a Premium to Market
July 26, 2021
FRAMINGHAM, MA / ACCESSWIRE / July 26, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing XCART™, a personalized CAR T...
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Xenetic Biosciences, Inc. Reports First Quarter 2021 Financial Results
May 12, 2021
- Continued Execution on Xcart™ Development Plan With Commencement of Exploratory Patient Biopsy Trial Expected To Position the Company To Conduct Ind-Enabling Studies in the United States - Licensing...
From
Xenetic Biosciences, Inc.
Via
AccessWire
Topics
Intellectual Property
Regulatory Compliance
Exposures
COVID-19
Intellectual Property
Legal
Xenetic Biosciences, Inc. to Present at the Q2 Virtual Investor Summit
May 10, 2021
Live video webcast with CEO, Jeffrey Eisenberg on Tuesday, May 18, 2021 at 3:30 PM ET FRAMINGHAM, MA / ACCESSWIRE / May 10, 2021 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"),...
From
Xenetic Biosciences, Inc.
Via
AccessWire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.